In an interview on Wednesday, Novavax Inc (NVAX.O) CEO John Jacobs said the company slashed $50 million in expenses in the first quarter of 2023 and aimed to cut more.
Jacobs also said Novavax is in frequent conversations with the FDA about the design of its 2023 COVID-19 booster injection and expects it to be available by autumn.
Novavax, Inc. in Gaithersburg, Maryland, develops vaccinations for dangerous infectious illnesses. Company scientists generated experimental influenza, respiratory syncytial virus, Ebola, and other infectious illness vaccines before 2020.
Comment Template